---
title: "Cancer Risk Varies by Clinical Subtype of Newly Diagnosed Type 2 Diabetes in the US"
id: "medrxiv-8-site-specific-cancer-incidence-among-clinical-subtypes-of-newly-diagnosed-type"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-8-site-specific-cancer-incidence-among-clinical-subtypes-of-newly-diagnosed-type"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.17.26360595v1?rss=1"
published_at: "2026-08-18T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cancer Risk Varies by Clinical Subtype of Newly Diagnosed Type 2 Diabetes in the US
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-8-site-specific-cancer-incidence-among-clinical-subtypes-of-newly-diagnosed-type
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.17.26360595v1?rss=1)
- **Published At:** 2026-08-18T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This matched retrospective cohort study used the Epic Cosmos Research Platform (2012–2025) to compare site-specific **cancer** incidence in adults with newly diagnosed **Type 2 diabetes (T2D)** versus matched adults without diabetes. - Researchers classified 575,139 adults with new T2D into four clinical subtypes using validated algorithms: **severe insulin-deficient (SIDD, 21.6%)**, **mild obesity-related (MOD, 23.5%)**, **mild age-related (MARD, 40.7%)**, and **mixed (14.1%)**. These were matched to 689,719 adults without diabetes on age, sex, and body mass index. - Median follow-up was 3.8 years. Overall cancer incidence was highest in the **MARD** group (17.3 per 1,000 person-years). - Compared with adults without diabetes, rates of **colorectal, pancreatic, liver, endometrial, and ovarian** cancers were elevated across T2D subtypes; the largest hazards were observed in **SIDD** (reported HR=3.87, 95% CI 3.51–4.27) and the mixed phenotype. - **Prostate cancer** incidence was lower in all T2D subtypes, most notably in **MOD** (HR=0.60, 95% CI 0.55–0.64). - **Breast cancer** rates diverged by subtype: higher in the mixed phenotype (HR=1.12, 95% CI 1.05–1.19) and lower in **MOD** (HR=0.85, 95% CI 0.80–0.90). - Uptake of screening—mammography and prostate-specific antigen testing—was lower across T2D subtypes compared with matched adults without diabetes. - The authors conclude that **site-specific cancer incidence and screening uptake differ by clinically defined T2D subtype**, and that subtype classification from routine clinical data could inform targeted cancer surveillance, but they note further study is needed before clinical implementation.
## Clinical Analysis & Structured Key Points
Site-Specific Cancer Incidence among Clinical Subtypes of Newly Diagnosed Type 2 Diabetes in the United States | medRxiv Skip to main content Site-Specific Cancer Incidence among Clinical Subtypes of Newly Diagnosed Type 2 Diabetes in the United States Zhongyu Li , Chang Liu , Mary Beth Weber , Mohammed K. Ali , Craig C. Hofmeister , View ORCID Profile Jithin Sam Varghese doi: https://doi.org/10.64898/2026.08.17.26360595 Zhongyu Li 1 Emory University Rolins School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: zhongyu.li{at}emory.edu Chang Liu 2 Emory University School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mary Beth Weber 2 Emory University School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mohammed K. Ali 3 Rollins School of Public Health: Emory University School of Public Health; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Craig C. Hofmeister 4 Department of Hematology & Medical Oncology, Winship Cancer Institute of Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jithin Sam Varghese 5 Emory University Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jithin Sam Varghese Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Type 2 diabetes (T2D) is associated with elevated rates of several cancers and is increasingly recognized as a heterogeneous disease, but whether its clinically distinct subtypes carry different cancer risks is unknown. Methods: In this matched retrospective cohort study using electronic health record data from the Epic Cosmos Research Platform (2012-2025), adults with newly diagnosed T2D were classified into severe insulin-deficient (SIDD, 21.6%), mild obesity-related (MOD, 23.5%), mild age-related (MARD, 40.7%), or mixed (14.1%) subtypes using validated algorithms and matched to adults without diabetes on age, sex, and body mass index. Cause-specific Cox models estimated adjusted hazard ratios (HRs) for seven site-specific cancers, accounting for competing risks. Cancer screening uptake was assessed as a secondary outcome. Results: Among 575,139 adults with T2D and 689,719 without diabetes (median follow-up, 3.8 years), MARD had the highest cancer incidence (17.3 per 1,000 person-years). Relative to adults without diabetes, rates of colorectal, pancreatic, liver, endometrial, and ovarian cancer were elevated across subtypes, with the highest hazards in SIDD (HR=3.87, 95% CI=3.51 to 4.27) and mixed phenotypes. Prostate cancer rates were lower in all subtypes, most markedly in MOD (HR=0.60, 95% CI=0.55 to 0.64). Rates of breast cancer were higher among mixed (HR=1.12, 95% CI=1.05 to 1.19) and lower among MOD (HR=0.85, 95% CI=0.80 to 0.90). Mammography and prostate-specific antigen screening were lower across subtypes. Conclusions: Site-specific cancer incidence and screening uptake differed across clinically defined subtypes of T2D. Subtype classification from routine clinical data may inform targeted cancer surveillance, though further study is needed before clinical use. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was exempt from ethical approval as it involved secondary analysis of pre-existing, HIPAA-limited, de-identified data from the Epic Cosmos Research Platform, which does not constitute human subjects research. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Epic Cosmos access is available through institutional representatives of participating institutions and the Epic Cosmos team after completing certification requirements. https://cosmos.epic.com Funder Information Declared Winship Cancer Institute, https://ror.org/02gars961 Emory Global Diabetes Research Center Pharmaceutical Research and Manufacturers of America Foundation Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 18, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Site-Specific Cancer Incidence among Clinical Subtypes of Newly Diagnosed Type 2 Diabetes in the United States Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Site-Specific Cancer Incidence among Clinical Subtypes of Newly Diagnosed Type 2 Diabetes in the United States Zhongyu Li , Chang Liu , Mary Beth Weber , Mohammed K. Ali , Craig C. Hofmeister , Jithin Sam Varghese medRxiv 2026.08.17.26360595; doi: https://doi.org/10.64898/2026.08.17.26360595 Share This Article: Copy Citation Tools Site-Specific Cancer Incidence among Clinical Subtypes of Newly Diagnosed Type 2 Diabetes in the United States Zhongyu Li , Chang Liu , Mary Beth Weber , Mohammed K. Ali , Craig C. Hofmeister , Jithin Sam Varghese medRxiv 2026.08.17.26360595; doi: https://doi.org/10.64898/2026.08.17.26360595 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Epidemiology Subject Areas All Articles Addiction Medicine (605) Allergy and Immunology (891) Anesthesia (324) Cardiovascular Medicine (4725) Dentistry and Oral Medicine (473) Dermatology (403) Emergency Medicine (635) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1605) Epidemiology (15741) Forensic Medicine (32) Gastroenterology (1192) Genetic and Genomic Medicine (6932) Geriatric Medicine (723) Health Economics (1045) Health Informatics (4922) Health Policy (1417) Health Systems and Quality Improvement (1720) Hematology (572) HIV/AIDS (1319) Infectious Diseases (except HIV/AIDS) (16203) Intensive Care and Critical Care Medicine (1152) Medical Education (657) Medical Ethics (150) Nephrology (714) Neurology (7112) Nursing (359) Nutrition (1066) Obstetrics and Gynecology (1215) Occupational and Environmental Health (990) Oncology (3552) Ophthalmology (1026) Orthopedics (384) Otolaryngology (440) Pain Medicine (463) Palliative Medicine (138) Pathology (701) Pediatrics (1763) Pharmacology and Therapeutics (729) Primary Care Research (754) Psychiatry and Clinical Psychology (5782) Public and Global Health (9626) Radiology and Imaging (2359) Rehabilitation Medicine and Physical Therapy (1417) Respiratory Medicine (1232) Rheumatology (631) Sexual and Reproductive Health (759) Sports Medicine (571) Surgery (755) Toxicology (106) Transplantation (300) Urology (283)
## Related Clinical Research

- [New-onset type 2 diabetes mellitus and risk of obesity-related cancers: UK Biobank matched cohort](https://medichelpline.com/clinical-feed/medrxiv-3-new-onset-type-2-diabetes-mellitus-and-obesity-related-cancer-risk-a-matched.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Rising Star Dillon Boulton, PhD: AR and Immune Modulation in ER+ Breast Cancer](https://medichelpline.com/clinical-feed/endocrine-news-0-star-power-2026-q-a-with-dillon-boulton-phd.md)
- [GLP-1 medications and temporary hair loss risk in type 2 diabetes](https://medichelpline.com/clinical-feed/medical-news-today-0-glp-1-drugs-linked-to-temporary-hair-loss-here-s-why.md)
- [Diabetes Mellitus and Cancer Risk: Epidemiology and Molecular Mechanisms](https://medichelpline.com/clinical-feed/pubmed-42364319.md) (DOI: 10.1016/j.bbrc.2026.154205)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.